NewAmsterdam Accounts Payable from 2010 to 2024

NAMS Stock   20.84  0.21  1.00%   
NewAmsterdam Pharma Accounts Payable yearly trend continues to be comparatively stable with very little volatility. Accounts Payable will likely drop to about 10 M in 2024. Accounts Payable is the amount NewAmsterdam Pharma owes to suppliers or vendors for products or services received but not yet paid for. It represents NewAmsterdam Pharma's short-term liabilities. View All Fundamentals
 
Accounts Payable  
First Reported
2010-12-31
Previous Quarter
16.9 M
Current Value
10 M
Quarterly Volatility
5.4 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check NewAmsterdam Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among NewAmsterdam Pharma's main balance sheet or income statement drivers, such as Tax Provision of 28.4 K, Net Interest Income of 3.6 M or Interest Income of 11.8 M, as well as many indicators such as Price To Sales Ratio of 68.31, Dividend Yield of 0.0 or PTB Ratio of 3.02. NewAmsterdam financial statements analysis is a perfect complement when working with NewAmsterdam Pharma Valuation or Volatility modules.
  
Check out the analysis of NewAmsterdam Pharma Correlation against competitors.
For more information on how to buy NewAmsterdam Stock please use our How to Invest in NewAmsterdam Pharma guide.

Latest NewAmsterdam Pharma's Accounts Payable Growth Pattern

Below is the plot of the Accounts Payable of NewAmsterdam Pharma over the last few years. An accounting item on the balance sheet that represents NewAmsterdam Pharma obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of NewAmsterdam Pharma are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. It is the amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities. NewAmsterdam Pharma's Accounts Payable historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in NewAmsterdam Pharma's overall financial position and show how it may be relating to other accounts over time.
Accounts Payable10 Years Trend
Slightly volatile
   Accounts Payable   
       Timeline  

NewAmsterdam Accounts Payable Regression Statistics

Arithmetic Mean3,410,576
Geometric Mean1,115,605
Coefficient Of Variation157.56
Mean Deviation4,287,823
Median487,060
Standard Deviation5,373,642
Sample Variance28.9T
Range16.4M
R-Value0.74
Mean Square Error14.2T
R-Squared0.54
Significance0
Slope886,209
Total Sum of Squares404.3T

NewAmsterdam Accounts Payable History

202410 M
202316.9 M
202211.9 M
2021M

About NewAmsterdam Pharma Financial Statements

NewAmsterdam Pharma shareholders use historical fundamental indicators, such as Accounts Payable, to determine how well the company is positioned to perform in the future. Although NewAmsterdam Pharma investors may analyze each financial statement separately, they are all interrelated. The changes in NewAmsterdam Pharma's assets and liabilities, for example, are also reflected in the revenues and expenses on on NewAmsterdam Pharma's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Accounts Payable16.9 M10 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for NewAmsterdam Stock Analysis

When running NewAmsterdam Pharma's price analysis, check to measure NewAmsterdam Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NewAmsterdam Pharma is operating at the current time. Most of NewAmsterdam Pharma's value examination focuses on studying past and present price action to predict the probability of NewAmsterdam Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NewAmsterdam Pharma's price. Additionally, you may evaluate how the addition of NewAmsterdam Pharma to your portfolios can decrease your overall portfolio volatility.